Copy to clipboard 
FDA approved Cerapedics’ Premarket Approval (PMA) supplement for i-FACTOR® Peptide Enhanced Bone Graft for use in anterior cervical discectomy and fusion to treat degenerative cervical disc disease. Cerapedics requested approval for an updated package insert that incorporates 24-month follow-up data from subjects enrolled in the original clinical study.
A review of 2-year follow-up data from an FDA Investigational Device Exemption clinical trial of i-FACTOR indicated its statistical superiority in overall clinical success to autograft in ACDF. Analysis of combined endpoints for overall success demonstrated 70% success for patients receiving i-FACTOR vs. 56% for those receiving autograft.
“We are pleased to receive FDA approval of our PMA supplement, which allows i-FACTOR labeling to reflect longer-term clinical data showing that the statistical superiority to autologous bone in overall clinical success that was observed at one year has been maintained at two-year follow-up,” said Jeffrey Marx, Ph.D., President and Chief Operating Officer. “We believe i-FACTOR Bone Graft represents one of the most important technological breakthroughs in this field and are committed to compiling extensive Level I human clinical data to support its use across the U.S. and around the world.”
Cerapedics launched i‑FACTOR in 2016. The drug/device combination is based on synthetic small peptide technology that accelerates new bone formation. It is in a new category of bone graft technology and is one of only two drug/device combination products approved by the FDA, joining Medtronic’s Infuse.
FDA approved Cerapedics' Premarket Approval (PMA) supplement for i-FACTOR® Peptide Enhanced Bone Graft for use in anterior cervical discectomy and fusion to treat degenerative cervical disc disease. Cerapedics requested approval for an updated package insert that incorporates 24-month follow-up data from subjects enrolled in the original...
FDA approved Cerapedics’ Premarket Approval (PMA) supplement for i-FACTOR® Peptide Enhanced Bone Graft for use in anterior cervical discectomy and fusion to treat degenerative cervical disc disease. Cerapedics requested approval for an updated package insert that incorporates 24-month follow-up data from subjects enrolled in the original clinical study.
A review of 2-year follow-up data from an FDA Investigational Device Exemption clinical trial of i-FACTOR indicated its statistical superiority in overall clinical success to autograft in ACDF. Analysis of combined endpoints for overall success demonstrated 70% success for patients receiving i-FACTOR vs. 56% for those receiving autograft.
“We are pleased to receive FDA approval of our PMA supplement, which allows i-FACTOR labeling to reflect longer-term clinical data showing that the statistical superiority to autologous bone in overall clinical success that was observed at one year has been maintained at two-year follow-up,” said Jeffrey Marx, Ph.D., President and Chief Operating Officer. “We believe i-FACTOR Bone Graft represents one of the most important technological breakthroughs in this field and are committed to compiling extensive Level I human clinical data to support its use across the U.S. and around the world.”
Cerapedics launched i‑FACTOR in 2016. The drug/device combination is based on synthetic small peptide technology that accelerates new bone formation. It is in a new category of bone graft technology and is one of only two drug/device combination products approved by the FDA, joining Medtronic’s Infuse.
You’ve reached your limit.
We’re glad you’re finding value in our content — and we’d love for you to keep going.
Subscribe now for unlimited access to orthopedic business intelligence.
JV
Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.
